fludarabine has been researched along with Granuloma, Hodgkin in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (9.52) | 18.2507 |
| 2000's | 22 (52.38) | 29.6817 |
| 2010's | 14 (33.33) | 24.3611 |
| 2020's | 2 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Afanasyev, B; Beynarovich, A; Borzenkova, E; Kondakova, E; Kozlov, A; Kulagin, A; Lepik, K; Mikhailova, N; Moiseev, I; Pirogova, O; Stelmakh, L; Volkov, N; Zalyalov, Y; Zubarovskaya, L | 1 |
| Beaven, AW; Brenner, MK; Buchanan, FB; Cheng, CJ; Dittus, C; Dotti, G; Eldridge, PW; Gee, AP; Grilley, BJ; Grover, NS; Heslop, HE; Ivanova, A; Lulla, PD; McKay, KL; Mehta, B; Morrison, K; Park, SI; Ramos, CA; Rooney, CM; Savoldo, B; Serody, JS; Shea, TC; Wang, T; Wu, MF | 1 |
| Albrecht, M; Bökkerink, J; Claviez, A; Dörffel, W; Holte, H; Karlen, J; Lüders, H; Mann, G; Marciniak, H; Niggli, F; Pötter, R; Rühl, U; Schellong, G; Schmiegelow, K; Schwarze, EW; Wickmann, L | 1 |
| Amital, H; Davidson, T; Kneller, A; Schiby, G; Twig, G; Yaniv, G; Zavdy, O | 1 |
| Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ | 1 |
| Alousi, AM; Anderlini, P; Champlin, RE; Fanale, MA; Hagemeister, FB; Hosing, CM; Khouri, IF; Ledesma, C; Neelapu, S; Nieto, Y; Oki, Y; Plair, T; Popat, UR; Romaguera, JE; Saliba, RM; Shpall, EJ; Younes, A | 1 |
| Bordigoni, P; Cachin, F; Curtillet, C; David, A; Demeocq, F; Dore, E; Halle, P; Isfan, F; Kanold, J; Merlin, E; Michel, G; Paillard, C; Rochette, E; Rousseau, R; Salmon, A | 1 |
| Sosnowski, M; Trusz-Gluza, M; Wita, K; Wróbel, W | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Bot, FJ; Chaker, L; Maartense, E; Segeren, CM | 1 |
| Burchette, J; Foo, WC; Huang, Q; Hutchinson, CB; Sebastian, S; Wang, E | 1 |
| Chen, R; Delioukina, M; Forman, S; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Rosenthal, J; Shen, J; Smith, E | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Acholonu, S; Alousi, AM; Anderlini, P; Champlin, RE; Chancoco, C; Ciurea, S; Fanale, MA; Hosing, CM; Khouri, IF; Ledesma, C; Nieto, Y; Popat, UR; Saliba, RM; Shpall, EJ; Valverde, R; Younes, A | 1 |
| Chen, DB; Shen, DH | 1 |
| Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D | 1 |
| Arima, N; Niino, D; Ohshima, K; Tsuda, H; Tsuji, T; Yamasaki, H | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Abebe, L; Adiga, GU; Wiernik, PH | 1 |
| Beyer, J; Claviez, A; Dörffel, W; Dreger, P; Ehninger, G; Klingebiel, T; Nürnberger, W; Schmitz, N; Suttorp, M | 1 |
| Abecasis, M; da Costa, FL; Miranda, N; Nave, M; Nunes, R; Passos-Coelho, JL | 1 |
| Barry, T; Ben Alon, D; Ben Dor, D; Blumental, R; Ducach, A; Lugassy, G; Nemets, A | 1 |
| Bucher, C; Buser, AS; Gratwohl, A; Heim, D; Passweg, JR; Tichelli, A | 1 |
| Nicolle, A; Proctor, SJ; Summerfield, GP | 1 |
| Boniver, J; de Leval, L; De Prijck, B; Du, MQ; Harris, NL; Isaacson, P; Vivario, M; Zhou, Y | 1 |
| Fong, D; Gastl, G; Kaiser, A; Spizzo, G; Tzankov, A | 1 |
| Amadori, S; de Fabritiis, P; Del Poeta, G; Fratoni, S; Maurillo, L; Niscola, P; Palombi, M; Piccioni, D; Principe, MI | 1 |
| Alvarez, I; Arranz, R; Caballero, D; Canales, M; Cavet, J; Garcia-Conde, J; Goldstone, AH; Hunter, A; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, D; Parker, A; Peggs, KS; Qian, W; Ribera, JM; Sanz, G; Sierra, J; Sureda, A; Thomson, K; Urbano-Ispizua, A | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, SA; Hagemeister, F; Hosing, C; Khouri, IF; Munsell, MF; Pro, B; Qazilbash, MH; Romaguera, J; Saliba, R; Ueno, NT; Younes, A | 1 |
| Dickmeiss, E; Heilmann, C; Jakobsen, B; Kornblit, B; Madsen, HO; Masmas, T; Olesen, G; Petersen, SL; Ryder, LP; Sengeløv, H; Svejgaard, A; Vindeløv, L | 1 |
| Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE | 1 |
| Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Ketterer, N; Moullet, I; Salles, G; Sonet, A; Thieblemont, C | 1 |
| Calvo Villas, J; Ramírez Sánchez, M; Sicilia Guillén, F | 1 |
| Barth, S; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Schinköthe, T; Schulz, H; Wittor, H | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Beltrami, G; Carella, AM; Carella, M; Corsetti, MT; Greco, M; Scalzulli, RP | 1 |
| Barrett, AJ; Carter, C; Childs, R; de Witte, M; Kang, EM; Leitman, SF; Little, R; Malech, H; Morgan, RA; Phang, S; Tisdale, JF | 1 |
| Da Prada, GA; Della Cuna, GR; Giorgiani, G; Giraldi, E; Landonio, G; Locatelli, F; Pedrazzoli, P; Schiavo, R; Siena, S; Zambelli, A | 1 |
| Diehl, V; Voliotis, D | 1 |
2 review(s) available for fludarabine and Granuloma, Hodgkin
| Article | Year |
|---|---|
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Fatal Outcome; Female; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lomustine; Male; Middle Aged; Mitoxantrone; Neoplasms, Multiple Primary; Neoplastic Stem Cells; Prednisone; Prognosis; Reed-Sternberg Cells; Remission Induction; Skin Neoplasms; Splenectomy; Tumor Virus Infections; Vidarabine; Vinblastine; Vincristine | 2003 |
Challenges in treating hematologic malignancies.
Topics: Anemia; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epoetin Alfa; Erythropoietin; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Prognosis; Quality of Life; Recombinant Proteins; Vidarabine | 2002 |
10 trial(s) available for fludarabine and Granuloma, Hodgkin
| Article | Year |
|---|---|
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Epitopes; Female; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Ki-1 Antigen; Lymphocyte Depletion; Male; Middle Aged; Stem Cell Transplantation; Vidarabine; Young Adult | 2020 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine | 2016 |
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult | 2012 |
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease Progression; Drug Therapy; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Melphalan; Methotrexate; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Topics: Adult; Disease-Free Survival; Female; Follow-Up Studies; Hodgkin Disease; Hospitals, University; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4 Lymphocyte Count; Disease Progression; Disease-Free Survival; Female; Fever; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisolone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 1998 |
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Melphalan; Pilot Projects; Transplantation Conditioning; Vidarabine | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
30 other study(ies) available for fludarabine and Granuloma, Hodgkin
| Article | Year |
|---|---|
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2022 |
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; International Agencies; Male; Neoplasm Grading; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2013 |
Richter syndrome: chronic lymphocytic leukemia transformation into Hodgkin's disease.
Topics: Antineoplastic Agents; Antiviral Agents; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Vidarabine | 2013 |
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adult; Brentuximab Vedotin; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lung Diseases; Male; Melphalan; Middle Aged; Nausea; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Myeloablative Agonists; Positron-Emission Tomography; Severity of Illness Index; Time Factors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2010 |
Diagnosis by sheer coincidence.
Topics: Aged; Antineoplastic Agents; Diuretics; Echocardiography, Doppler; Female; Heart Failure; Hodgkin Disease; Humans; Incidental Findings; Pulmonary Subvalvular Stenosis; Tomography, X-Ray Computed; Transposition of Great Vessels; Vidarabine | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Haemophagocytic syndrome and Hodgkin's disease variant of Richter's syndrome after fludarabine for CLL.
Topics: Aged; Antineoplastic Agents; Epstein-Barr Virus Infections; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Vidarabine | 2010 |
Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative dis
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Cell Transformation, Neoplastic; Clone Cells; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Immunoblastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Plasma Cells; Vidarabine | 2010 |
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
[Classic Hodgkin's lymphoma in post-treatment hairy cell leukemia: report of a case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Leukemia, Hairy Cell; Male; Mitoxantrone; Neoplasms, Multiple Primary; Rituximab; Splenectomy; Vidarabine; Vinblastine | 2011 |
Epstein-Barr virus-negative classical Hodgkin's lymphoma in a patient with T-cell prolymphocytic leukemia treated with fludarabine.
Topics: Antineoplastic Agents; Female; Herpesvirus 4, Human; Hodgkin Disease; Humans; Leukemia, Prolymphocytic, T-Cell; Middle Aged; Neoplasms, Second Primary; Vidarabine | 2012 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Prednisone; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Vincristine | 2003 |
Reversible acute renal failure following single administration of fludarabine.
Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Combined Modality Therapy; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Cyclophosphamide; Disease Progression; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Second Primary; Syndrome; Time Factors; Vidarabine | 2003 |
High dose chlorambucil in the treatment of lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vidarabine | 2004 |
Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection.
Topics: Aged; Antineoplastic Agents; Clone Cells; DNA, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Deletion; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasms, Second Primary; Polymerase Chain Reaction; Reed-Sternberg Cells; Vidarabine | 2004 |
Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.
Topics: Antineoplastic Agents; Cell Transformation, Viral; Clone Cells; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Hodgkin Disease; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Micromanipulation; Middle Aged; Reed-Sternberg Cells; Vidarabine | 2005 |
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasms, Second Primary; Rituximab; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2008 |
Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Topics: Adult; Aged; Denmark; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Hospitalization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Outpatient Clinics, Hospital; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality Therapy; Cytarabine; Factor VIII; Female; Granulocyte Colony-Stimulating Factor; Hemophilia A; Hemorrhage; Hodgkin Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Plasmapheresis; Prednisone; Procarbazine; Prothrombin; Remission Induction; Thrombocytopenia; Vidarabine; Vincristine | 1995 |
Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 1999 |
[Chronic lymphatic leukemia and Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasms, Second Primary; Prednisone; Remission Induction; Vidarabine; Vinblastine | 1999 |
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Cells; Bone Marrow Cells; DNA Primers; DNA, Neoplasm; Gene Duplication; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Hodgkin Disease; Humans; Immunization, Passive; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Oligonucleotide Probes; Polymerase Chain Reaction; Reference Standards; Rituximab; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 2000 |
Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease.
Topics: Antineoplastic Agents; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Salvage Therapy; Transplantation, Homologous; Vidarabine | 2001 |
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Cyclophosphamide; Cyclosporine; Feasibility Studies; Ganciclovir; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infection Control; Leukemia, Myeloid; Prednisone; Premedication; Recurrence; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine; Viral Load | 2002 |
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Renal Cell; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Pilot Projects; Sarcoma; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |